Treatment of IgA1 deposition diseases
AssigneeTufts Medical Center, Inc.
InventorsAndrew G. Plaut, Jiazhou Qiu
Life of this patent
Estimating the term…
Abstract
The present invention discloses the use of bacterial IgA1 proteases to treat IgA1 deposition in tissue and organs. Bacterial IgA1 proteases specifically cleave IgA1 molecules and thus provide a means to specifically cleave and remove IgA1 depositions. Accordingly, therapeutic agents for the treatment of diseases characterized by IgA deposition are provided. In particular, therapeutic agents to treat IgA nephropathy, Dermatitis herpetiformis (DH), and Henoch-Schoenlein purpura (HS) are disclosed.
Claims9
A method comprising a step of administering to an individual having deposits of human IgA1 an IgA1 protease selected from the group consisting of Streptococcus pneumoniae IgA1 protease, Streptococcus sanguis IgA1 protease, Clostridium ramosum IgA1 protease, Haemophilus influenzae IgA1 protease, Haemophilus aegyptius IgA1 protease, Neisseria meningitidis IgA1 protease, and Neisseria gonorrhoeae IgA1 protease, such that the deposits of human IgA1 are reduced.
A method comprising a step of administering to an individual having deposits of human IgA1 a therapeutically effective amount of an isolated polypeptide molecule comprising a first amino acid sequence comprising an IgA1 protease selected from the group consisting of Streptococcus pneumoniae IgA1 protease, Streptococcus sanguis IgA1 protease, Clostridium ramosum IgA1 protease, Haemophilus influenzae IgA1 protease, Haemophilus aegyptius IgA1 protease, Neisseria meningitidis protease, and Neisseria gonorrhoeae IgA1 protease, and a second amino acid sequence comprising a tag, such that the deposits of human IgA1 are reduced.
Dependencies are inferred from the claim text.